BEST2

Across TCGA pan-cancer cohorts, BEST2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated BEST2 data layer compared with 21 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher BEST2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated BEST2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

PDAC, LSCC, and LUAD are the cancer types where BEST2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.492	1.000	.001	16	view →
LSCC	DFS	Tertile	II,III,IV	0.919	0.218	.006	6	view →
LUAD	DFS	Quartile	III,IV	0.264	0.875	.010	5	view →
CCRCC	OS	Tertile	III,IV	0.791	1.000	.022	4	view →
HNSC	OS	Tertile	All	0.923	0.837	.033	3	view →
GBM	OS	Tertile	All	0.721	0.914	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

BEST2–PDAC (DFS)

Open the PDAC breakdown →